The stock of ReShape Lifesciences Inc (RSLS) has seen a -3.93% decrease in the past week, with a -46.11% drop in the past month, and a -80.38% decrease in the past quarter. The volatility ratio for the week is 2.74%, and the volatility levels for the past 30 days are at 19.64% for RSLS. The simple moving average for the past 20 days is -26.43% for RSLS’s stock, with a -96.75% simple moving average for the past 200 days.
Is It Worth Investing in ReShape Lifesciences Inc (NASDAQ: RSLS) Right Now?
Additionally, the 36-month beta value for RSLS is 1.25. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for RSLS is 2.39M and currently, short sellers hold a 1.41% ratio of that float. The average trading volume of RSLS on June 25, 2025 was 3.01M shares.
RSLS) stock’s latest price update
ReShape Lifesciences Inc (NASDAQ: RSLS) has experienced a decline in its stock price by -2.10 compared to its previous closing price of 2.62. However, the company has seen a fall of -3.93% in its stock price over the last five trading days. globenewswire.com reported 2025-06-25 that Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia
RSLS Trading at -58.21% from the 50-Day Moving Average
After a stumble in the market that brought RSLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.38% of loss for the given period.
Stock Fundamentals for RSLS
Current profitability levels for the company are sitting at:
- -0.83 for the present operating margin
- 0.63 for the gross margin
The net margin for ReShape Lifesciences Inc stands at -0.89. The total capital return value is set at 34.73. Equity return is now at value -120.16, with -47.07 for asset returns.
Based on ReShape Lifesciences Inc (RSLS), the company’s capital structure generated 1.35 points at debt to capital in total, while cash flow to debt ratio is standing at -4.58.
Currently, EBITDA for the company is -6.67 million with net debt to EBITDA at -0.04. When we switch over and look at the enterprise to sales, we see a ratio of 0.8. The receivables turnover for the company is 8.11for trailing twelve months and the total asset turnover is 1.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.53.
Conclusion
In conclusion, ReShape Lifesciences Inc (RSLS) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
